Apotex Health Corp's stock is on the rise, reflecting investor confidence and strategic growth.
In the latest trading session, Apotex Health Corp (APTX.TO) saw its stock price increase by 1.63%, closing at CA$37.96. This uptick comes amid positive developments that could boost the company's reputation and financial standing in the market.
Advertisement
Apotex Health Corp
APTX.TO
APTX.TO
Apotex Health Corp
WealthAwesomeAdvertisement
Market cap
$8.62B
P/E
22.8x
52W high
$40.18
52W low
$26.05
1W change
-4.77%
Analyst Price Targets
Based on analyst covering APTX
Wall Street analysts forecast APTX stock price to rise 15.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$41.24
+15.5% Upside
Current Price
C$35.71
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APTX's historical volatility
30-Day Vol
49.0%
Annualized
90-Day Vol
51.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$42.69
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$37.90 | C$32.00 – C$44.88 |
| 60 trading days | C$40.22 | C$31.67 – C$51.09 |
| 90 trading days | C$42.69 | C$31.85 – C$57.22 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: For Canadian investors, Apotex's recent performance may signal a strong outlook, especially as the company navigates its recent IPO and strategic initiatives.
Market cap now at CA$8.99 billion
With a market cap of CA$8.99 billion, Apotex Health Corp is a significant player in the Canadian pharmaceutical landscape, showcasing its growth potential.
Bull case
The recent investment-grade issuer rating from Morningstar DBRS could lower borrowing costs and improve operational flexibility, making Apotex a more appealing investment option.
Bear case
Even with the positive movement, investors should stay cautious. The pharmaceutical sector can be volatile, and unexpected regulatory challenges might affect future performance.
Advertisement
Positive Developments Fueling Growth
Apotex Health Corp's recent 1.63% gain is linked to its strategic financial moves, including the investment-grade issuer rating from Morningstar DBRS. This rating boosts its credibility and allows for lower borrowing costs, which could enhance its operational capabilities. For more details, check out our analysis on APTX.TO.
Market Performance and Future Outlook
Closing at CA$37.96, Apotex's market cap has reached CA$8.99 billion, solidifying its position in the pharmaceutical sector. Investors are closely watching how the company leverages its recent IPO and the approval of its generic semaglutide for chronic weight management. This could set the stage for sustained growth in the coming quarters. Explore more about its performance on APTX.TO.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
